bioMérieux S.A. (BMXXY)

OTCMKTS · Delayed Price · Currency is USD
14.55
+1.95 (15.48%)
At close: Jan 14, 2026
Market Cap13.02B -8.7%
Revenue (ttm)4.84B +8.3%
Net Income443.81M -8.1%
EPS3.72 -8.6%
Shares Outn/a
PE Ratio29.34
Forward PE19.25
Dividend0.06 (0.39%)
Ex-Dividend DateJun 10, 2025
Volume100
Average Volume8,607
Open14.55
Previous Close12.60
Day's Range14.55 - 14.55
52-Week Range12.35 - 14.62
Beta0.66
RSIn/a
Earnings DateFeb 27, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]

Sector Healthcare
Founded 1963
Employees 14,754
Stock Exchange OTCMKTS
Ticker Symbol BMXXY
Full Company Profile

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR Financial Statements

News

bioMérieux S.A. (BMXXY) Analyst/Investor Day Transcript

bioMérieux S.A. (OTCPK:BMXXY) Analyst/Investor Day November 4, 2025 8:30 AM ESTCompany ParticipantsAymeric FichetPierre Boulud - Chief Executive...

3 months ago - Seeking Alpha

bioMérieux S.A. 2025 Q2 - Results - Earnings Call Presentation

The following slide deck was published by bioMérieux S.A.

5 months ago - Seeking Alpha

bioMérieux S.A. (BMXMF) Q4 2024 Earnings Call Transcript

bioMérieux S.A. (OTCPK:BMXMF) Q4 2024 Results Conference Call March 7, 2025 8:00 AM ET Company Participants Aymeric Fichet - Investor Relations Pierre Boulud - Chief Executive Officer Guillaume Bouhou...

1 year ago - Seeking Alpha

bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript

bioMérieux S.A. (OTCPK:BMXMF) Q2 2024 Results Conference Call September 5, 2024 8:00 AM ET Company Participants Aymeric Fichet - IR Pierre Boulud - Chief Executive Officer Guillaume Bouhours - CFO Con...

1 year ago - Seeking Alpha

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2021 Results - Earnings Call Transcript

4 years ago - Seeking Alpha

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q3 2021 Results - Earnings Call Transcript

4 years ago - Seeking Alpha

bioMérieux: Pioneering In Vitro Diagnostics

bioMérieux is a leading developer and producer of in vitro diagnostic solutions with a focus on infectious diseases. The Company has a solid financial structure to support growth.

4 years ago - Seeking Alpha

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript

bioMérieux S.A. (BMXMF) CEO Alexandre Mérieux on Q4 2020 Results - Earnings Call Transcript

5 years ago - Seeking Alpha